Sinovac Biotech Financials - Benzinga

SPY765.04−0.07%QQQ738.11+0.21%BTC/USD83,958.21+0.60%DIA512.94−0.21%GLD381.97+1.07%TLT78.37−0.32%

Sinovac Biotech Ltd

SVANASDAQ

Trade with Public

Trade with Public

$5.85

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Sinovac Biotech Financials

Sinovac Biotech (SVA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY

Sinovac Biotech (NASDAQ:SVA) reported quarterly losses of $(0.84) per share. This is a 1500 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $147.079 million in

Benzinga Newsdesk

PRO
Sinovac Biotech H1 Adj. EPS $0.06 Down From $1.18 YoY, Sales $130.270M Up From $128.711M YoY

Sinovac Biotech (NASDAQ:SVA) reported quarterly earnings of $0.06 per share. This is a 94.92 percent decrease over earnings of $1.18 per share from the same period last year. The company reported $130.270 million in

Benzinga Newsdesk

PRO
SINOVAC H1 EPS $(0.11) Down From $(0.15) YoY; Sales $121.3M Down From $140.4M YoY

Benzinga Newsdesk

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Vandana Singh

PRO
SINOVAC Reports Unaudited First Half 2021 Sales Results Of $11B, Up From $67.7M YoY

Benzinga Newsdesk

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)

Shanthi Rexaline

© 2026 Benzinga | All Rights Reserved